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ABSTRACT We previously established that the trefoil
peptides (TFFs) pS2, spasmolytic polypeptide, and
intestinal trefoil factor are involved in cellular scatter-
ing and invasion in kidney and colonic cancer cells.
Using the chorioallantoic membrane (CAM) assay and
the formation of tube-like structures by human umbil-
ical vein endothelial cells (HUVEC) plated on the
Matrigel matrix substratum, we report here that TFFs
are proangiogenic factors. Angiogenic activity of TFFs
is comparable to that induced by vascular endothelial
growth factor, leptin, and transforming growth fac-
tor-. Stimulation of angiogenesis by pS2 in the CAM
assay is blocked by pharmacological inhibitors of cyclo-
oxygenase COX-2 (NS-398) and epidermal growth fac-
tor receptor (EGF-R) tyrosine kinase (ZD1839), but is
independent of KDR/Flk-1 and thromboxane A2 recep-
tors. In contrast, the morphogenic switch induced by
pS2 in HUVEC cells could be inhibited by the specific
KDR heptapeptide antagonist ATWLPPR and by inhib-
itors of COX-2 and EGF-R signaling. These results
implicate TFFs in the formation of new blood vessels
during normal and pathophysiological processes linked
to wound healing, inflammation, and cancer progres-
sion in the digestive mucosa and other human solid
tumors associated with aberrant expression of TFFs.—
Rodrigues, S., Van Aken, E., Van Bocxlaer, S., Attoub,
S., Nguyen, Q.-D., Bruyneel, E., Westley, B. R., May,
F. E. B., Thim, L., Mareel, M., Gespach, C., Emami, S.
Trefoil peptides as proangiogenic factors in vivo and in
vitro: implication of cyclooxygenase -2 and EGF recep-
tor signaling. FASEB J. 17, 7–16 (2003)
The hallmark of progression of human colorectal tu-
mors from the early premalignant stages is the acquisi-
tion of the invasive phenotype and formation of new
blood vessels within the adenomas and adenocarcino-
mas (1). There is evidence to support a critical role for
the inflammatory processes and mucosal ulceration in
the emergence of gastrointestinal tumors (2–4). Pa-
tients with inflammatory bowel disease have an in-
creased risk of developing intestinal neoplasms.
Chronic inflammatory disorders, diabetic retinopathy,
tissue ischemia, and tumor angiogenesis are character-
ized by the branching and sprouting of new blood
vessels. The development of solid tumors promotes
mobilization of the differentiated endothelium of pre-
existing vascular cells at the vicinity of the neoplastic
tissues and the recruitment of bone marrow-derived
endothelial progenitors and hematopoietic stem cells
(5–7). Angiogenesis also occurs in healthy individuals
during wound healing and other physiologic regula-
tions in the female reproductive tract (8). Several
clinical and experimental studies indicate that angio-
genesis is critical for the growth and persistence of solid
tumors and is strongly associated with the metastatic
cascade. The coordinated control of tumor cell inva-
sion, survival, and angiogenesis allows tumor cells to
invade distant organs during the complex processes of
the metastatic cascade. A tumor mass that is smaller
than 0.4 mm in diameter can receive oxygen and
nutriments by simple diffusion. However, without sur-
rounding blood vessels, primary colonic tumors 3 mm3
in size are not able to survive (9). Induction of the
angiogenic switch is the consequence of local hypoxia
and absolute requirements of growing primary tumors
on oxygen, nutriments, and survival factors (9–11).
The formation of new vascular structures during cancer
progression is primarily mediated by the proliferation,
migration, and morphogenesis of endothelial cells in-
duced by proangiogenic and chemotactic factors stim-
ulating the migratory phenotype through direct and
indirect mechanisms involving paracrine and autocrine
regulatory loops. Thus, numerous angiogenic factors
are produced locally by cancer cells, endothelial cells,
and stromal and blood cells. Positive and negative
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regulators of angiogenesis are stored in the ECM as
active or inactive forms, at the multiple interfaces
between tumor cells and the other cell types within the
tumor stroma. Tumor angiogenesis and vascular re-
modeling during chronic inflammation are controlled
by numerous angiogenic activators and mitogens such
as vascular endothelial growth factors (VEGFs), fibro-
blast growth factors, cyclooxygenase COX-2, transform-
ing growth factor- (TGF-), and agonists of the epi-
dermal growth factor receptors (EGF-R) such as TGF-
(10–15). Accordingly, we recently demonstrated that
the neoplastic progression of human colorectal tumors
is associated with early and sustained increase in VEGF
transcripts and expression of members of the VEGF
family (VEGF-B, VEGF-C) and their tyrosine kinase
receptors FLT-1, KDR, and FLT-4 (1).
Trefoil peptides (TFFs) are overexpressed during
peptic ulceration, in inflammatory bowel diseases
(Crohn disease, colitis), and during the early stages of
human colon cancer progression (16, 17). The trefoil
peptide family, comprising pS2, spasmolytic polypep-
tide (SP) and intestinal trefoil factor (ITF), plays a key
role in wound healing and mucosal repair in the
digestive tract, tumor cell scattering, migration, sur-
vival, and invasiveness (16–23). Overexpression of TFFs
and pS2 was originally observed in several solid human
tumors including breast, pancreas, prostate, and stom-
ach (16, 24–28), suggesting local autoregulation of
transforming functions by trefoil peptides (17). Expres-
sion of the breast cancer-associated pS2 peptide is
closely associated with premalignant stages in human
gastric mucosa (24) and with neuroendocrine differen-
tiation of prostate cancers via an estrogen-independent
pathway (25, 27). In agreement, pS2 was negative in
patients with benign prostate hyperplasia whereas 92%
of patients at risk with prostate cancer are positive for
pS2 expression (28). Recent studies designated the
possible contribution of the EGF-R mitogen-activated
protein kinase cascade in trefoil peptide-mediated sig-
naling, leading to decreased cell–cell and cell–substra-
tum adhesion (23) or transcriptional inter-regulations
(29, 30). We recently demonstrated that external addi-
tion of TFFs or constitutive overexpression of pS2
promotes cellular scattering and invasion in kidney and
colonic epithelial cells through cyclooxygenase- and
thromboxane A2 receptor (TXA2-R) -dependent mech-
anisms (17, 19). These two cellular activities implicated
in tumor cell invasion and metastasis are required for
endothelial cell migration, proliferation, and forma-
tion of new microvasculature during establishment of
the angiogenic cascade in solid tumors. Therefore, we
reasoned that TFFs might also exert angiogenic func-
tions in normal physiological processes during embry-
onic development and formation of vascular-like struc-
tures by endothelial cells in vivo and in vitro.
In this study, we set out to compare the angiogenic
potential of trefoil peptides and well-recognized proan-
giogenic factors, including the secreted form of VEGF-
165, TGF-, and leptin (13, 31). We first examined the
angiogenic activity of the trefoil factors pS2, SP, and
ITF on the chick chorioallantoic membrane (CAM)
assay. The possible implication of COX-2 and the
EGF-R was examined, with special reference to the
EGF-R tyrosine kinase inhibitor ZD1839 (Iressa), an
anilinoquinazoline derivative that blocks transforming
functions controlled by the EGF-R agonists TGF-,
amphiregulin, and EGF in kidney and colonic cancer
cells (32, 33). Second, we investigated the capacity of
TFFs to induce the formation of capillary-like structures
by primary human umbilical vein endothelial cells
(HUVEC) in culture (34). Using these experimental
approaches, we now provide evidence that TFFs are
functioning as angiogenic factors in vivo and in vitro.
MATERIALS AND METHODS
Cell culture
Primary cultures of HUVEC were obtained from Clonetics-
BioWhittaker (Emerainville, France) and maintained at 37°C
using the EBM-2 bullet kit from BioWhittaker supplemented
with 2% fetal calf serum, endothelial cell growth supplement
(containing VEGF, human FGF-B, IGF-1, and human EGF),
50 g/mL heparin, 100 IU/mL penicillin, 100 g/mL strep-
tomycin, 2.5 g/mL amphotericin B, and supplements hydro-
cortisone, ascorbic acid, gentamicin, and insulin (BioWhit-
taker). Cells used in the experiments were between passages
5 and 15.
Chick CAM assay
The CAM angiogenesis assay was performed as described by
Maragoudakis et al. (35), with some modifications (36).
Fertilized chicken eggs (Nauwelaerts, Oostakker, Belgium)
were incubated for 3 days at 37°C with 70% humidity. On day
3, albumen was removed to detach the developing CAM from
the shell. On day 4, a small window was opened on the
eggshell (exposing the CAM) and covered with cellophane
tape. The eggs were returned to the incubator until day 9,
when the test compounds diluted at the indicated concentra-
tions in control vehicle buffer (250 L were placed on sterile
plastic disks (11 mm diameter), which were allowed to dry
under sterile conditions. A solution of cortisone acetate (100
g/disk; Sigma; Saint-Quentin Fallavier, France) was incor-
porated in all disks. On each CAM, the disk containing
control vehicle was placed 1 cm away from the disk containing
the test compound. The windows were covered and eggs were
incubated until day 11, when angiogenesis was assessed. The
eggs were flooded with 10% buffered formalin, the plastic
disks were removed, and the eggs were kept at room temper-
ature for at least 2 h. A large area around the disks was cut off
and placed on a glass slide, and the vascular density index was
measured by the method of Harris-Hooker et al. (37). A grid
containing three concentric circles of 6, 8, and 10 mm
diameter was positioned on the CAM surface. Each experi-
mental determination involved counting of angiogenic vessels
on five to eight separate eggs. All vessels intersecting the
circles were counted. Most stimulation and inhibition exper-
iments were repeated one to four times together with buffer
vehicle controls. The angiogenic response in a given CAM
assay was analyzed using the box plot representation (38) in
which each box bounds the first and third quartiles (referred
to as the interquartile range) encompassing 50% of the data
and includes the median, upper, and lower hinges, as indi-
cated by horizontal lines within the box. Dispersion of the
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data above and below this range is marked by vertical bars that
extend to the most extreme values, including the adjacent
values inside the upper and lower fences, and by individual
outliers beyond this range (filled circles). The box plot
illustrates unusual distributions, sample size in each group,
and the confidence interval about the median. The signifi-
cance of the differences between experimental values was
assessed by the Mann Whitney-U test and P values 0.05 were
considered to be statistically significant.
In vitro capillary formation of HUVEC cells plated
on Matrigel
Assessment of in vitro capillary formation used growth factor-
reduced Matrigel (Becton Dickinson, Le Pont de Claix,
France). Matrigel is a squamous cell carcinoma basement
membrane matrix composed primarily of collagen IV, lami-
nin, entactin, and heparan sulfate proteoglycans. The Matri-
gel matrix was thawed, gently mixed to homogeneity using
cooled pipettes, and diluted v/v with the EBM-2 culture
medium (BioWhittaker France). Matrigel supplemented or
not with angiogenic peptides and other effectors was used to
coat the wells of 96-well plates. After solidification of the
Matrigel suspension (50 Lwell) for 1 h at 37°C, 35,000
HUVECs were plated to each well and incubated for 4 and 8 h
at 37°C in 0.2 mL of EBM-2 medium containing 2% FCS,
heparin, hydrocortisone, ascorbic acid, and gentamicin with-
out endothelial cell growth supplement. Then cells were
photographed using a Nikon inverted phase contrast pho-
tomicroscope (Nikon, Eclipse TE300, Microme´canique, Evry,
France) coupled with video image analysis (Microme´-
canique). The tubular network growth area was compared in
control and effector-treated Matrigel matrix. Tube formation
was quantified by counting the number of tube-like structures
formed in each microwell.
Peptides and Chemicals
Human SP and ITF were produced in yeast and purified as
described (39, 40); the recombinant Ser58 analog of human
pS2 produced in Escherichia coli was purified by affinity and
ion exchange chromatography, followed by gel filtration
(41). VEGF-165 and leptin were from R&D System Europe
Ltd.(Oxon, UK). The EGF-R agonist TGF- was from Sigma.
The selective COX-2 inhibitor NS-398 and the JAK-2 tyrosine
kinase inhibitor AG490 were from Calbiochem (Meudon,
France). The EGF-R tyrosine kinase inhibitor ZD1839
(Iressa), also designated ZD in the present study, was from
AstraZeneca (Macclesfield, UK). In tyrosine kinase assays, the
inhibitory potency of ZD1839 on the EGF-RTK occurs at IC50
concentrations ranging from 23 to 80 nM (42). Inhibition of
the KDR and c-erbB-2 tyrosine kinases occurs, but at doses
100-fold higher than EGF-RTK inhibition. No other activity
has been demonstrated against a wide range of other kinases.
The prostaglandin H2/TXA2-R antagonist SQ29,548 (desig-
nated as SQ295 in the present study) was from Cayman
Chemicals (Ann Arbor MI, USA). The KDR antagonist AT-
WLPPR (43), designated A7 in the present study, was from
Neosystem (Strasbourg, France).
RESULTS
Induction of angiogenesis in vivo by trefoil peptides
in the CAM assay
We performed initial experiments to test the ability of
recombinant trefoil peptides (TFFs) to function as
proangiogenic factors in vivo. We used the CAM assay
involving the coordination and integration of multicel-
lular responses during development of the chick em-
bryo.
As shown in Fig. 1, pS2, SP, and ITF promoted a
remarkable stimulation of new vessel formation that
was comparable to that induced by the proangiogenic
factor VEGF-165. Angiogenic activity of the trefoil
peptides was dose dependent for both pS2 and ITF
(Fig. 2), with a threshold stimulation observed at the
dose of 1.75 ng pS2/disk (P0.01) and 16.7 ng ITF/
disk (P0.01) compared with the control DMEM me-
dium.
The possible contribution of VEGF receptors to
angiogenesis promoted by external addition of the
trefoil factor pS2 was investigated in the CAM assay. We
tested blocking activity of the ATWLPPR heptapeptide
(A7), which was recently shown to abolish VEGF-
induced angiogenesis in vivo, through direct binding to
KDR and competition against the functional interac-
tions between VEGF and KDR (43). Indeed, VEGF is
thought to induce angiogenesis by engaging VEGF
receptors 2 (VEGF-R2), also known as KDR and Flk-1.
As shown in Fig. 3, the blocking peptide was inefficient
Figure 1. Chorioallantoic membrane angiogenesis induced by
trefoil peptides and VEGF. On day 9, each CAM was exposed
to either 55 nM VEGF-165 (250 ng/disk) or the trefoil
peptides pS2, SP, and ITF (100 nM) as a solution correspond-
ing to 175 ng pS2, 300 ng SP, and 167 ng ITF/disk. DMEM
refers to the buffer control used as vehicle. After 48 h of
incubation, CAMs were examined with a macroscope to count
the angiogenic vessels. Each substance was analyzed with 8
embryos in parallel as described in Materials and Methods.
Angiogenesis was scored in a double-blind procedure for
each embryo by estimating the number and extent of vessel
branch points in the area of the disk. The angiogenic activity
in the CAM assay is calculated from the formula: angiogenic
index  (t-c)/c  100, where t equals the number of
intersections in the area covered by the test disk and c the
number of intersections of any vessel in the area covered by
the control disk in the same egg. The significance of the
differences between the control angiogenic index (DMEM)
and the other experimental values was assessed by the Mann
Whitney test. P values  0.05 were considered to be statisti-
cally significant. All growth factors considered induced signif-
icant stimulation of angiogenesis (*P0.01).
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against the angiogenic response induced by pS2 in the
CAM assay, but abolished the formation of new blood
vessels induced by VEGF-165. The KDR antagonist A7
alone was ineffective on control angiogenic activity.
Thus, A7 selectively prevented angiogenesis promoted
by VEGF in our CAM assay.
We next investigated the potential role of the EGF-R
signaling pathway in angiogenesis evoked by VEGF,
leptin, and pS2. The EGF-R is activated by a family of
regulatory growth factors including EGF, TGF-, and
amphiregulin. EGF and TGF- are overexpressed in
gastrointestinal cancer cells and act as paracrine and
autocrine mitogenic and angiogenic agents in human
digestive cancer and other solid tumors of breast,
prostate, and pancreas (13, 44–46). As shown in Fig. 4,
addition of the EGF-R agonist TGF- in the CAM assay
dose-dependently increased angiogenesis; this was abol-
ished by simultaneous addition of the EGF-R tyrosine
kinase inhibitor ZD1839 (ZD). The antitumor effect of
ZD1839 was accompanied by inhibition of microvessel
counts in human colonic xenografts and depletion of
proangiogenic growth factors such as VEGF, TGF-,
and fibroblast growth factor (47). Similarly, ZD1839
reversed by 70% the VEGF angiogenic activity in our
studies, whereas the formation of new blood vessels
induced by pS2 was completely suppressed by this
tyrosine kinase inhibitor. Our findings imply that the
proangiogenic effect of pS2 is highly dependent on the
functional activity of the EGF-R. Consistent with our
data, recent studies indicate that ITF signaling is linked
to transactivation of the EGF-R tyrosine kinase during
establishment of the migratory phenotype in human
colonic cancer cells HT29 (23, 30). In contrast, leptin-
induced angiogenesis was not inhibited by ZD1839 but
was completely inhibited by the Janus kinase JAK-2
tyrosine kinase inhibitor AG490 (Fig. 4). Indeed, leptin
receptors Ob-Rb were shown to oligomerize and, upon
leptin interaction, activate JAK-2 via transphosphoryla-
tion (48). Conversely, AG490 did not inhibit pS2-
induced angiogenesis. We found that ZD1839 specifi-
cally inhibited proangiogenic signals induced by
TGF-, VEGF, and pS2 and did not affect angiogenesis
linked to the activation of the Ob-Rb by leptin. Thus,
our data reveal that the EGF-R is implicated in the
proangiogenic activity of VEGF and pS2 using the CAM
assay.
We have reported that trefoil peptides exert scatter-
ing and proinvasive activities in kidney and colonic
cancer cells through cyclooxygenase- and TXA2-R-de-
pendent signaling pathways (17, 19). Elevated levels of
cyclooxygenase COX-2 are detected at an early stage in
colorectal neoplasia during adenoma formation and in
adenocarcinomas (49–51). COX-2 is frequently unde-
tectable in normal tissues but is induced in gastrointes-
tinal epithelial cells and endothelial cells in response to
hypoxia, inflammatory cytokines, oxygen radicals, and
cellular transformation by the SRC oncogene (19, 52).
In solid tumors, COX-2 is localized in neoplastic cells,
microvascular endothelial cells, interstitial macro-
phages, and stromal fibroblasts. The contribution of
COX-2 in tumor angiogenesis (53) is associated with
increased expression of VEGF (54), production of the
eicosanoids TXA2, PGE2, and prostacyclins that are
directly involved in the migratory and invasive pheno-
types of endothelial and tumor cells (19, 55–57). Pros-
taglandins E2 in turn were recently shown to trans-
activate the EGF-R, a signaling response directly
connected with the growth of colon cancer (58). There-
fore, COX-2 signaling through its eicosanoid products
plays a key role in inflammation, carcinogenesis, tumor
invasion, and angiogenesis in several solid tumors of
the gastrointestinal tract, breast, and prostate. Several
experimental and clinical studies have demonstrated
Figure 3. Effect of the KDR antagonist A7 on chorioallantoic
membrane angiogenesis induced by pS2 and VEGF. The
ATWLPPR heptapeptide A7 (200 M, 42 g/disk) efficiently
and specifically inhibited the angiogenic response produced
by VEGF-165 (250 ng/disk) in the CAM assay (*P0.01) but
was ineffective on the proangiogenic activity of pS2 (100 nM,
175 ng pS2/disk).
Figure 2. Dose-dependent stimulation of chorioallantoic
membrane angiogenesis by the trefoil peptides pS2 and ITF.
Chorioallantoic membranes were treated with various con-
centrations of pS2 (0.1-100 nM) as a solution containing
different amounts of trefoil peptides (0.175-175 ng pS2/disk)
and ITF (1-100 nM, 1.67 to 167 ng/disk). After 48 h of
incubation, CAMs were examined with a macroscope to count
the angiogenic vessels. Significance of the differences be-
tween the control angiogenic index (DMEM) and other
experimental values was assessed by the Mann Whitney test.
Threshold stimulations compared with the control DMEM,
*P  0.01.
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that nonsteroidal anti-inflammatory drugs such as su-
lindac, piroxicam, and NS-398 inhibit angiogenesis
through direct effects on endothelial cells. These
COX-2 inhibitors reduce the number and size of intes-
tinal polyps in patients with familial adenomatous pol-
yposis and abolish tumor cell invasion induced by
trefoil peptides and the SRC oncogene (19, 59–61).
Because COX-2 has been implicated in endothelial cell
motility and formation of capillary-like structures
through a TXA2-R dependent mechanism (55, 62), we
next examined the possible contribution of COX-2 and
the TXA2-R in the determination of proangiogenic
activity of pS2 in the CAM assay.
We tested the effect of the COX-2 inhibitor NS-398 at
a starting concentration of 100 nM (7.8 ng/disk)
corresponding to total inhibition of cellular invasion
and TXA2 production induced by pS2 and src in
HCT8/S11 human colonic cancer cells (19). Under
these conditions, NS-398 abrogated angiogenesis in-
duced by VEGF and pS2 (Fig. 5). In contrast, the
TXA2-R antagonist SQ295 was ineffective against the
angiogenic response evoked by pS2. In agreement,
CAM angiogenesis was not affected by the TXA2-R
agonist U466 (not shown), suggesting that the proan-
giogenic effect of pS2 is independent of TXA2 and its
receptors. Of several positive angiogenic factors pro-
duced by cyclooxygenases, PGE2 was recently demon-
strated to induce VEGF expression in rat gastric micro-
vascular endothelial cells, suggesting that autocrine
VEGF regulation of endothelial cell proliferation, mi-
gration, and morphogenesis can take place in tumor
angiogenesis (57). There is solid evidence that hypoxia
signals and disruption of intercellular junctions be-
tween endothelial cells involving the VE-cadherin sys-
tem up-regulate VEGF generation by endothelial cells
(8–11, 63–65). Consistent with these findings, the
existence of an autocrine loop for induction of the
VEGF gene and accumulation of VEGF through activa-
tion of the VEGF receptor KDR has been reported in
human dermal microvascular endothelial cells (66).
These observations suggest that angiogenesis involves a
self-amplification mechanism that is primed by VEGF
produced by tumor cells in a first step, then by autoin-
duction of VEGF expression in endothelial cells. Ac-
cordingly, Fig. 5 shows that simultaneous addition of
VEGF and pS2 did not produce additive responses.
Thus, single addition of each proangiogenic peptide
induced maximal stimulation and saturation of the
angiogenic capacity in the CAM assay.
Induction of capillary-like structures in HUVEC
by trefoil peptides in vitro
To assess whether the proangiogenic effect of TFFs
involves a direct interaction of the peptides with endo-
thelial cells, we conducted comparative studies on the
formation of capillary-like structures in vitro, using
HUVEC plated on Matrigel-coated plates. As shown in
Fig. 6A, normal and transformed human endothelial
cells have the ability to form capillary structures when
seeded and cultured for 8 h on top of Matrigel substra-
tum (34, 66, 67). Control cells move from their initial
Figure 4. Effect of the tyrosine kinase inhibitors
ZD1839 and AG490 on chorioallantoic membrane
angiogenesis induced by TGF-, VEGF, pS2, and
leptin. Angiogenesis was strongly induced by in-
creasing concentrations of the EGF-R agonist
TGF- (5 and 100 nM, corresponding to 7.5 and
150 ng TGF-/disk, respectively) or single addi-
tion of VEGF (250 ng/disk), pS2 (175 ng/disk),
and 6.25 nM leptin (100 ng/mL, 25 ng/disk). The
EGF-R tyrosine kinase inhibitor ZD1839 (1 M,
112 ng/disk) abrogated the angiogenic response
promoted by TGF- (100 nM, 150 ng/disk) or pS2
(*P0.01), reduced by 75% the stimulatory effect
of VEGF (P0.04), but was ineffective on the
proangiogenic activity of leptin. In contrast, JAK-2
tyrosine kinase inhibitor AG490 (50 M, 3.65
g/disk) selectively blocked leptin-induced angio-
genesis.
Figure 5. Effect of the cyclooxygenase COX-2 inhibitor NS-
398 and the TXA2-R antagonist SQ295 on chorioallantoic
membrane angiogenesis induced by VEGF and pS2. The
COX-2 inhibitor NS-398 (100 nM, 7.8 ng/disk) inhibits
VEGF- and pS2-induced angiogenesis in the chicken CAM
(P0.01 and P0.005, respectively; *P0.01), whereas the
TXA2-R antagonist SQ295 (30 M, 2.9 g/disk) was ineffec-
tive. Nevertheless, combined addition of VEGF and pS2
showed no additional response compared with the angio-
genic index measured in the presence of each effector alone.
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uniform pattern of dispersed cell layers and associate to
form a network of cell clusters connected by long,
multicellular processes leading to the formation of
tube-like structures. This spontaneous angiogenic phe-
notype is enhanced by addition of the growth factors
VEGF, pS2, and leptin in the Matrigel matrix (Fig. 6A
and Fig. 7) and involves endothelial cell migration and
capillary tube formation. Simultaneous addition of the
KDR inhibitor A7 resulted in a strong inhibition of the
angiogenic responses to VEGF and pS2 (Fig. 6A and
Fig. 7). Similarly, up to 60–70% inhibition of tube-like
structures induced by VEGF and pS2 was observed in
HUVEC cell cultures treated by EGF-R and COX-2
inhibitors (Fig. 6B and Fig. 7). However, the KDR
antagonist A7 and the COX-2 inhibitor NS-398 were
ineffective against the migratory phenotype induced by
leptin in HUVEC grown on Matrigel (Figs. 6 and 7).
The crucial role of the EGF-R in angiogenesis is further
supported by the observation that the capillary-like
structures in HUVEC cells were interrupted by the
tyrosine kinase inhibitor ZD1839.
DISCUSSION
We show in this study that trefoil peptides are proan-
giogenic regulators in vivo and in vitro, suggesting
direct interactions between these gastrointestinal pep-
tides and endothelial cells. The VEGF receptor KDR
seems to mediate almost all the observed angiogenic
responses to VEGF-165 in the CAM assay and the
formation of tube-like structures induced by VEGF and
pS2 in HUVEC, using growth factor-reduced conditions
in the culture medium and Matrigel matrix substratum.
In contrast, angiogenesis promoted by pS2 in the CAM
assay was not abolished by the KDR antagonist A7,
suggesting functional redundancies in vivo and a per-
missive action of KDR signaling on the proangiogenic
activity of pS2 on endothelial cells in vitro (Fig. 8).
Accordingly, the spontaneous angiogenic phenotype
was blocked effectively in control HUVEC incubated
for 8 and 16 h in the presence of the KDR antagonist A7
Figure 6. Patterns of angiogenesis induced by human umbilical vein endothelial cells (HUVEC) cultured on Matrigel matrix in
the presence or absence of the proangiogenic factors VEGF-165, pS2, and leptin: selective inhibition by the KDR antagonist A7
and inhibitors of the EGF-R tyrosine kinase (ZD1839) and cyclooxygenase COX-2 (NS-398). Cultured HUVEC cells were plated
onto layers of growth factor reduced basement membrane Matrigel matrix containing the following proangiogenic factors:
VEGF (2.2 nM), pS2 (100 nM), leptin (6.25 nM), or control buffer containing 2% FCS, as vehicle (control). A) Effects of the
KDR antagonist A7 (50 M) and B) inhibitors of the EGF-R tyrosine kinase (ZD1839, 1 M) and COX-2 (NS-398, 100 nM). Cells
were photographed 4 and 8 h after plating 35,000 HUVEC in 96-well plates. Photographs (magnification: 40) are
representative of 3 other experiments using two separate microwells, illustrating the whole surface of each well. For
quantification, see Fig. 7.
Figure 7. Quantification of tubular morphogenesis induced
by VEGF, pS2, and leptin in HUVEC cells cultured in the
presence or absence of the KDR antagonist A7 and pharma-
cological inhibitors of the EGF-R tyrosine kinase (ZD1839)
and COX-2 (NS-398). HUVEC cells were cultured under the
experimental conditions described in legend to Fig. 6. Tube
formation was determined by the length of tube-like struc-
tures containing connected cells. Data are means  se from
4 separate experiments. Asterisks indicate that significantly
different values were obtained in the presence of the indi-
cated inhibitors vs. the corresponding control stimulation
(P0.001-0.024, unpaired Student’s t test).
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(not shown), suggesting self-activation of the VEGF-R
KDR/Flk-1 through autocrine loops. A similar situation
was observed for the proangiogenic activity of leptin,
acting via EGF-R independent pathways in the CAM
assay, whereas the EGF-R tyrosine kinase inhibitor
ZD1839 abrogated leptin-induced tube-like formation
in HUVEC. Thus, the EGF-R is required for the proan-
giogenic action of leptin in vitro, suggesting the inter-
esting hypothesis that the morphogenic effect of leptin
is dependent on the functional activity of the EGF-R
tyrosine kinase. For elucidation of the underlying
mechanism of VEGF165- and pS2-induced angiogenesis
in HUVEC cells, recent studies have demonstrated that
VEGF165 bind with high affinity to the neuropilin
receptors NP1 and NP2 (68). NP1 is a multifunctional
130 kDa transmembrane receptor binding placenta
growth factor-2, heparin, and semaphorin 3A, a com-
pletely unrelated protein family implicated in axon
guidance and cell migration (69, 70). In contrast, NP2
binds to semaphorin 3C and 3F with high affinity and
mediates repulsion of sympathetic neurons (70). Ex-
pression of NP1 in endothelial cells enhances affinity
labeling of VEGF165 to the VEGFR-2 KDR/Flk-1 recep-
tor and VEGF165-induced endothelial chemotaxis (71).
Since NP1 forms a coreceptor complex with KDR/Flk-1
in the presence of the VEGF165 ligand (73), it is
tempting to consider that NP1 govern, at least in part,
the substantial proangiogenic activity of pS2 and
VEGF165 at the NP1 and/or NP1-KDR receptor com-
plex in HUVEC. Thus, neutralization of VEGFR-2 by
the A7 blocking peptide in the present study might
affect the angiogenic responses mediated through the
KDR-NP1 complex. Because the HUVEC are reported
to contain functional NP1 (71, 72), our data leave open
the interesting question of whether neuropilins and
their ligands, including the potent angiogenic factor
VEGF165, are directly or indirectly implicated in the
proangiogenic functions of trefoil peptides (Fig. 8).
Further studies are required, using neutralizing anti-
bodies directed against NP1 or NP2 or an antagonist
peptide that competes for VEGF-165 binding at the
KDR/NP1 complex (72).
We have demonstrated that angiogenesis promoted
by VEGF and pS2 in vivo and in vitro was prevented by
inhibitors of the EGF-R tyrosine kinase (ZD1839) and
COX-2 (NS-398). Our data further implicate cyclooxy-
genases and EGF-R signaling pathways in the determi-
nation of the angiogenic phenotype in normal and
pathological processes. In contrast, leptin was found to
promote formation of tube-like structures in HUVEC in
a COX-2 and KDR -independent manner. As expected,
the proangiogenic activity of leptin was prevented by
the JAK-2 tyrosine kinase inhibitor AG490 in the CAM
assay. The signaling capacity of activated Ob-Rb include
JAK-2 activation, direct recruitment of STAT3 and the
tyrosine phosphatase SHP-2, and a number of down-
stream signals linked to immediate and delayed cellular
responses regulating cell proliferation, invasion, and
transcriptional regulations (48, 73). VEGF-driven an-
giogenic responses are mediated by KDR and require
the concerted activity of COX-2 and the EGF-R tyrosine
kinase in vivo and in vitro. Most interestingly, when the
CAM was exposed to the conditioned media (CM-pS2)
prepared from pS2-transformed HCT8/S11-pS2 hu-
man colonic cancer cells (19), a strong angiogenic
response was observed, using an A7- and KDR-depen-
dent pathway (not shown). Control CM prepared from
parental HCT8/S11 cells was inactive. Our data support
the existence of a proangiogenic factor secreted by
pS2-transformed cancer cells and during inflammatory
responses associated with pS2 overexpression.
Trefoil peptides have been shown to mediate physi-
ologic functions in the normal digestive tract linked to
maintenance of the integrity of the gastrointestinal
mucosa. These beneficial functions controlled by TFFs
include wound repair and mucosal protection against
local injury induced by ulceration and inflammatory
and apoptotic signals (16). We have added important
information that the beneficial effects of TFFs result
from their ability to act as proangiogenic factors in
normal endothelial cells. Thus, we have determined
that TFFs can contribute to physiological processes in
which neovascularization plays an important role dur-
Figure 8. Proposed model of the proangiogenic activity of
TFFs in vivo and in vitro. Cyclooxygenase COX-2 and the
EGF-R exert critical roles in the proangiogenic functions
controlled by TFFs through KDR-dependent and -indepen-
dent signaling pathways, according the cellular context in
vivo and in vitro. The COX-2 product PGE2 (PG) has been
reported to trans-activate the EGF-R and to up-regulate the
expression and release of VEGF from endothelial cells
through the prostaglandin EP receptor (EP-R). Similarly,
VEGF-driven angiogenic responses are mediated by KDR and
require the concerted activity of COX-2 and the EGF-R
tyrosine kinase in vivo and in vitro. A possible contribution of
the membrane receptors neuropilins (NP-1 and NP-2) in the
proangiogenic activity of trefoil peptides in vitro should be
considered, in view of their ability to interact with VEGF165.
For example, NP-1 was shown to enhance the binding of
VEGF165 to KDR and potentiate VEGF165-dependent migra-
tion of endothelial cells through the formation of a hetero-
trimeric complex. Together, our data suggest that trefoil
peptides are acting as beneficial proangiogenic factors during
normal vascularization, wound healing, and mucosal protec-
tion. Conversely, our data also support that TFFs can mediate
adverse effects on tumor angiogenesis, invasion, and resis-
tance to apoptosis during neoplastic progression.
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ing normal development. Conversely, we have previ-
ously shown that TFFs can exert undesirable effects in
the context of neoplasia by acting as scatter factors and
proinvasive agents on cancer cells (17, 19, 20). This
latter prediction is well sustained by the interdepen-
dence of TFFs and several signaling pathways playing a
key role in the cancerous progression of the human
digestive mucosa. These oncogenic pathways include
src, the Rho-like small GTPases, PI3	-kinases (17, 19,
20), and signaling through COX-2 and the EGF-R
tyrosine kinase in the present study. These signaling
pathways play a critical role in endothelial cell prolifer-
ation, migration, morphogenesis, and survival. Thus,
we hypothesize that TFFs may contribute to tumor
angiogenesis and metastasis through the induction of
an invasive and angiogenic tumor phenotype. The ITF
mRNA and protein are both induced by hypoxia in
confluent human colonic epithelial cells Caco-2, in
agreement with the presence of the HIF-1 binding
sequence 5	-TACGTGGG-3	 identified at positions –129
to –122 within the ITF promoter (74). Tumor hypoxia
is a powerful and early signal for induction of the
angiogenic switch (9, 10). Hypoxic regions of solid
tumors trigger the induction of the heterotrimeric
transcription factor hypoxia-inducible factor (HIF).
The HIF-2 subunit binds as a heterodimer with
HIF-1 to the hypoxia response element of a wide
variety of genes implicated in angiogenesis, cell prolif-
eration, and survival including VEGF, Flt-1, endothe-
lin-1, nitric oxide synthase 2, plasminogen inhibitor 1,
and several elements of the IGF pathways (75). Activa-
tion of the  HIF heterodimer is dependent on
stabilization of an O2-dependent degradation domain
of the  subunit by the ubiquitin-proteasome pathway
(76). Thus, the constitutive overexpression of TFFs
observed during the neoplastic progression in the
digestive tract strongly suggests that they belong to
the inflammation- and hypoxia-dependent proangio-
genic factors released from tumor cells. Because TFFs
are overexpressed in breast, prostate, and pancreatic
tumors, our findings suggest a general role for TFFs
in tumor angiogenesis and, possibly, in other physio-
pathological processes involving neovascularization.
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